Evotec SE (EVT.DE XETRA) 06 Apr 2026 earnings preview: valuation test ahead

EVT.DE stock trades at EUR 4.50 intraday on XETRA as Evotec SE prepares to report results on 08 Apr 2026. Investors will watch revenue cadence, margin progress and client milestones from partnerships with Bayer and Novo Nordisk. Today’s volume is 618409.00 versus an average of 818181.00, showing muted participation ahead of the print. We examine valuation, model forecasts and key catalysts that could re-rate the Healthcare name in Germany.

Earnings preview: what to watch for EVT.DE stock

Evotec reports on 08 Apr 2026 and guidance or contract updates will drive the move. Analysts will focus on gross margin, contract research revenue, and any milestone receipts from partners. Recent trends show year-to-date shares down -19.30%, and the last twelve months price range is EUR 4.00 to EUR 8.57. A beat on milestones could push near-term price discovery; misses would likely test the EUR 4.00 support.

Financial snapshot and valuation of Evotec SE EVT.DE

Evotec’s trailing metrics show EPS -0.90 and a reported P/E of -5.03, reflecting losses. Price-to-sales is 1.06 and price-to-book is 1.00, with a current ratio of 2.12. Market cap stands at EUR 800230764.00 with 177710585.00 shares outstanding. These figures frame a recovery trade if earnings show improving cash conversion and narrowing loss trends.

Meyka AI rates EVT.DE with a score out of 100 and forecast

Meyka AI rates EVT.DE with a score of 65.34 out of 100, grade B and suggestion HOLD. This grade factors in S&P 500 comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a monthly price of EUR 6.57 and a yearly price of EUR 2.79. Compared with the current price EUR 4.50, the monthly projection implies an upside of 46.00% while the yearly projection implies a downside of -38.00%. Forecasts are model-based projections and not guarantees.

Technicals, liquidity and trading on XETRA for EVT.DE stock

Intraday range today is EUR 4.33 to EUR 4.58 and the 50-day average is EUR 5.38. Momentum indicators show RSI near 42.35, ADX 33.23 and ATR 0.25, suggesting direction with moderate volatility. Average volume is 818181.00 and today’s relative volume at 0.76 signals lighter trade. Traders should watch the EUR 4.00 support and EUR 5.09 upper Bollinger band for breakout clues.

Risks, catalysts and sector context for EVT.DE stock

Key risks include recurring operating losses, negative free cash flow per share of -0.50, and interest coverage that remains weak. Sector peers in Healthcare trade with average P/E near 29.13, highlighting a valuation gap for Evotec. Catalysts that could narrow the gap include milestone receipts, partnership expansions, or margin improvement from higher service volumes. Watch macro funding conditions that affect biotech contracting and M&A flows.

Price targets, analyst-style outlook and strategy for EVT.DE stock

We set a conservative price target at EUR 3.00, a base target at EUR 5.50, and a bullish target at EUR 8.50 for a 12-month horizon. These targets reflect PB near parity, improving revenue per share, and a possible re-rating if milestones accelerate. For intraday traders, use tighter stops; for longer-term investors, require clearer cash flow improvement and milestone visibility before buying.

Final Thoughts

EVT.DE stock trades at EUR 4.50 on XETRA on 06 Apr 2026, with earnings due on 08 Apr 2026 and mixed near-term signals. Financials show EPS -0.90, P/E -5.03 and PB 1.00, highlighting a company in transition. Meyka AI’s models project a monthly level of EUR 6.57 and a yearly level of EUR 2.79, implying a possible short-term upside of 46.00% or a longer-term downside of -38.00% versus the current price. The Meyka grade of 65.34 (B, HOLD) balances recovery potential against execution risk. Traders should weigh milestone exposure and partnership progress against weak cash flow metrics and sector comparators. We link recent coverage from MarketBeat and Investing.com for context and note that Meyka AI provides this as AI-powered market analysis, not investment advice.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.